SERUM AND ENDOMETRIAL TISSUE ENDOCAN LEVELS IN PATIENTS WITH ENDOMETRIAL POLYPS, HYPERPLASIA AND CANCER

Introduction: Endocan is a proteoglycan which participates in inammation and angiogenesis. This study aims to determine whether serum and endometrial tissue concentrations of endocan can be used to differentiate between benign and malignant endometrial pathologies. Materials And Methods: This is a cross-sectional review of 90 patients who underwent endometrial biopsy due to abnormal vaginal bleeding and who were diagnosed with endometrial polyp (n=65), endometrial hyperplasia (n=12) and endometrial cancer (n=13) at the study center. Results: When compared to the endometrial cancer patients, the patients with endometrial polyp had signicantly younger age and longer height (p=0.001 and p=0.003 respectively). When compared to the endometrial cancer patients, the patients with endometrial hyperplasia had signicantly younger age and less frequent menopause (p=0.01 and p=0.001 respectively). The patients with endometrial hyperplasia had signicantly higher gravidity than the patients with endometrial polyp (p=0.020). The patients with endometrial polyp, endometrial hyperplasia and endometrial cancer had statistically similar concentrations of endocan in serum and endometrial tissue (p=0.249 and p=0.675 respectively). Conclusion: The patients with endometrial polyp, endometrial hyperplasia and cancer were statistically similar with respect to the endocan concentrations in serum and endometrial tissue.